Skip to main content

Advertisement

Table 1 Summary of the prognosis part of included studies

From: Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis

StudyRegionGalectin typesSample sizeHigh expression (%)Age (mean or median)Sex (M/F)PathologyStage or gradeResultSurvival analysisHR (95% CI)Cutoff valueSample sourceDetection methodFollow-up (months)
Chen [19]USAGalactin-14395NRNRPDACNROSU4.90 (1.788–13.426)Positive cells ≥ 5%TissueIHC72
Tang [17]ChinaGalactin-16671.2155 (37–83)45/21PDACTNM I-IVOSM4.676 (1.963–11.134)Positive cells > 30%TissueIHC78
Shimamura [20]JapanGalactin-31045062 (45–82)62/42PDACTNM I-IVOSM0.48 (0.28–0.81)Positive cells ≥ 60%TissueIHC104
Gaida [21]GermanyGalactin-313080.8066 (39–85)74/56PDACTNM I-IVOSKM0.85 (0.49–1.47)Positive cells ≥ 1%TissueIHC40
Shimura [24]JapanGalactin-32147.6267.114/7PCTNM I-IIIOSM4.559 (1.176–17.685)10.2 ng/mlSerumImmunoassay66
Maftouh [26]ItalyGalactin-42055.00NR9/11PDACT3N0(1)MxOSKM0.64 (0.25–1.68)Staining score ≥ medianTissueIHC45
DFSKM0.87 (0.33–2.26)
Hu [27]SwedenGalactin-414079.3069 (63–73)66/74PDACTNM I–IVOSM0.636 (0.380–1.063)Positive cells ≥ 10%TissueIHC60
DFSM0.638 (0.371–1.095)
Sideras [28]NetherlandsGalactin-914853.30NRNRPCGrade I-IIIOSM0.62 (0.40–0.97)0.4 (out of 3)TissueIHC175
DFSU0.6 (0.43–0.85)
  1. DFS disease-free survival, HR hazard ratio, IHC immunohistochemistry, KM Kaplan–Meier analysis, M/F male/female, M multivariate analysis, NR not reported, OS overall survival, PC pancreatic cancer, PDAC pancreatic ductal adenocarcinoma, U univariate analysis